Clinical Trials List
Protocol NumberLT-004
Active
2024-03-01 - 2026-03-31
Phase II
Recruiting3
ICD-10C22.9
Malignant neoplasm of liver, not specified as primary or secondary
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.2
Malignant neoplasm of liver, not specified as primary or secondary
-
Trial Applicant
CHEERY PHARMA CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 陳奎安 無
- Shi-Ming Lin 無
- 周宏學 無
- 李勁樵 無
- Chan-Keng Yang 無
- Wei-Chen Lee 無
- 滕威 無
- 吳庭榕 無
- 王瑜肇 無
- Chia-Hsun Hsieh 無
- 賴盈傑 無
- 林伯庭 無
- 李兆偉 無
- 鄭志軒 無
- 吕嘉偉 無
- Yi-Chung Hsieh 無
- 吳宗翰 無
- 洪豪謙 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 范峻維 無
- 文寄銘 無
- 鍾智淵 無
- 柯志燃 無
- Chun-Lung Feng 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
27 participants
-
Global
54 participants
